|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125085 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-21 10:29:11 |
|
注册时间: Date of Registration: |
2026-05-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
圆锥角膜家系的遗传学多中心研究 |
|
Public title: |
Multicenter Genetic Study of Keratoconus Families? |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
圆锥角膜家系的遗传学多中心研究 |
|
Scientific title: |
Multicenter Genetic Study of Keratoconus Families? |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李兴勇 |
研究负责人: |
陈世豪 |
|
Applicant: |
Xingyong Li |
Study leader: |
Shihao Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 577 88068862 |
研究负责人电话:
Study leader's |
+86 577 88068862 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lixy@eye.ac.cn |
研究负责人电子邮件: Study leader's E-mail: |
csh@eye.ac.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
温州市学院西路270号温州医科大学附属眼视光医院屈光手术中心 |
研究负责人通讯地址: |
浙江省温州市学院西路270号 |
|
Applicant address: |
270, West Xueyuan Road, Refractive Surgery Center, Eye Hospital, Wenzhou Medical University, Wenzhou |
Study leader's address: |
270 West Xueyuan Road, Wenzhou, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
温州医科大学附属眼视光医院 |
||
|
Applicant's institution: |
Eye Hospital, Wenzhou Medical University |
||
|
研究负责人所在单位: |
温州医科大学附属眼视光医院 |
||
|
Affiliation of the Leader: |
Eye Hospital, Wenzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
温医大眼视光伦审2026研第104号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
温州医科大学附属眼视光医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics committee of Eye Hospital of Wenzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-10 00:00:00 | ||
|
伦理委员会联系人: |
谷佩秋 |
||
|
Contact Name of the ethic committee: |
Gu Peiqiu |
||
|
伦理委员会联系地址: |
浙江省温州市学院西路270号 |
||
|
Contact Address of the ethic committee: |
270 West Xueyuan Road, Wenzhou, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 577 88075582 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
gupeiqiu@126.com |
|
研究实施负责(组长)单位: |
温州医科大学附属眼视光医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Eye Hospital, Wenzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省温州市学院西路270号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
270 West Xueyuan Road, Wenzhou, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
温州医科大学附属眼视光医院1010计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
1010 Program Project of Eye Hospital, Wenzhou Medical University |
||||||||||||||||||||||
|
研究疾病: |
圆锥角膜 |
||||||||||||||||||||||
|
Target disease: |
keratoconus |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本项目将通过开展多中心研究,基于遗传测序探索圆锥角膜的致病基因和位点。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project will conduct a multicenter study to explore the pathogenic genes and loci of keratoconus based on genetic sequencing. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.先证者有至少一只眼睛被确诊为原发性圆锥角膜; 2.家系至少包括先证者及其父母3人参与; 3.家系参与成员同意参与此项研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. The proband must have at least one eye diagnosed with primary keratoconus; 2. The family pedigree must include at least the proband and both parents (a minimum of 3 participants); 3. All participating family members have agreed to participate in this study. |
||||||||||||||||||||||
|
排除标准: |
1.先证者诊断为非原发性圆锥角膜,例如继发性圆锥角膜; 2.家系参与人员数量不足,无法达到研究要求; 3.家系参与者的临床数据或生物样本缺失,无法达到研究要求。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The proband is diagnosed with non-primary keratoconus, e.g., secondary keratoconus; 2. The number of participating family members is insufficient to meet the study requirements; 3. The clinical data or biological samples from the family participants are missing, failing to meet the study requirements. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2030-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2030-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不适用 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not Applicable |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
所有数据将于入组时采集,数据采集后将进行数据脱敏处理。数据将由专人进行管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All data will be collected at the time of enrollment. After data collection, the data will undergo anonymization processing. The data will be managed by designated personnel. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |